Editor: What To Know
- IGAP), innovator of GlucoTrack®, a non-invasive device and digital health platform for measuring glucose levels in people with Type 2 diabetes and prediabetes, announced today that it has completed its corporate name and ticker symbol change on the Nasdaq Capital Market, to be effective at the commencement of trading today, March 14, 2022.
- Registered stockholders holding their shares of common stock in book-entry or through a bank, broker or other nominee form do not need to take any action in connection with these changes.
- is a Delaware corporation, with headquarters in the United States and an R&D site in Or Yehuda, Israel.
GlucoTrack, Inc. (Nasdaq: GCTK) (“GlucoTrack” or the “Company”), formerly known as Integrity Applications, Inc., (Nasdaq: IGAP), innovator of GlucoTrack®, a non-invasive device and digital health platform for measuring glucose levels in people with Type 2 diabetes and prediabetes, announced today that it has completed its corporate name and ticker symbol change on the Nasdaq Capital Market, to be effective at the commencement of trading today, March 14, 2022.
The corporate name change and ticker symbol change do not affect the rights of the Company’s stockholders nor the number of outstanding shares of the Company’s common stock.
Registered stockholders holding their shares of common stock in book-entry or through a bank, broker or other nominee form do not need to take any action in connection with these changes.
For those stockholders holding physical stock certificates, the Company’s transfer agent, American Stock Transfer & Trust Company, will send instructions for exchanging those certificates for new certificates representing the new name and ticker symbol. Any shareholders with questions may reach American Stock Transfer & Trust Company at (877) 248-6417.
GlucoTrack, Inc. (NASDAQ: GCTK), (formerly known as Integrity Applications, Inc.) is focused on the design, development, and commercialization of non-invasive glucose monitoring technologies for people with type 2 diabetes and prediabetes. The Company has developed GlucoTrack®, a proprietary non-invasive glucose monitoring device designed to obtain glucose level measurements without the pain, incremental cost, difficulty, or discomfort of conventional invasive finger stick devices. GlucoTrack, Inc. is a Delaware corporation, with headquarters in the United States and an R&D site in Or Yehuda, Israel. For more information, please visit https://www.integrity-app.com/ and https://www.glucotrack.com.
